These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25921288)

  • 1. A review of typhoid fever transmission dynamic models and economic evaluations of vaccination.
    Watson CH; Edmunds WJ
    Vaccine; 2015 Jun; 33 Suppl 3(Suppl 3):C42-54. PubMed ID: 25921288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study.
    Lo NC; Gupta R; Stanaway JD; Garrett DO; Bogoch II; Luby SP; Andrews JR
    J Infect Dis; 2018 Nov; 218(suppl_4):S232-S242. PubMed ID: 29444257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study.
    Bilcke J; Antillón M; Pieters Z; Kuylen E; Abboud L; Neuzil KM; Pollard AJ; Paltiel AD; Pitzer VE
    Lancet Infect Dis; 2019 Jul; 19(7):728-739. PubMed ID: 31130329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.
    Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z;
    Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of typhoid vaccination in a prolonged typhoid outbreak setting: the case of Kasese district in Uganda.
    Carias C; Walters MS; Wefula E; Date KA; Swerdlow DL; Vijayaraghavan M; Mintz E
    Vaccine; 2015 Apr; 33(17):2079-85. PubMed ID: 25712333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine.
    Simanjuntak CH; Paleologo FP; Punjabi NH; Darmowigoto R; Soeprawoto ; Totosudirjo H; Haryanto P; Suprijanto E; Witham ND; Hoffman SL
    Lancet; 1991 Oct; 338(8774):1055-9. PubMed ID: 1681365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Typhoid fever vaccination strategies.
    Date KA; Bentsi-Enchill A; Marks F; Fox K
    Vaccine; 2015 Jun; 33 Suppl 3(Suppl 3):C55-61. PubMed ID: 25902360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness.
    Burrows H; Antillón M; Gauld JS; Kim JH; Mogasale V; Ryckman T; Andrews JR; Lo NC; Pitzer VE
    Vaccine; 2023 Jan; 41(4):965-975. PubMed ID: 36586741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in Typhoid Fever Epidemiology.
    Crump JA
    Clin Infect Dis; 2019 Feb; 68(Suppl 1):S4-S9. PubMed ID: 30767000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance.
    Andrews JR; Baker S; Marks F; Alsan M; Garrett D; Gellin BG; Saha SK; Qamar FN; Yousafzai MT; Bogoch II; Antillon M; Pitzer VE; Kim JH; John J; Gauld J; Mogasale V; Ryan ET; Luby SP; Lo NC
    Lancet Infect Dis; 2019 Jan; 19(1):e26-e30. PubMed ID: 30170987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of typhoid - a review.
    Frempong SN; Sutton AJ; Davenport C; Barton P
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):601-607. PubMed ID: 30037288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings.
    Antillón M; Bilcke J; Paltiel AD; Pitzer VE
    Vaccine; 2017 Jun; 35(27):3506-3514. PubMed ID: 28527687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community.
    Poulos C; Bahl R; Whittington D; Bhan MK; Clemens JD; Acosta CJ
    J Health Popul Nutr; 2004 Sep; 22(3):311-21. PubMed ID: 15609784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of the Economic Evidence of Typhoid Fever and Typhoid Vaccines.
    Luthra K; Watts E; Debellut F; Pecenka C; Bar-Zeev N; Constenla D
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S83-S95. PubMed ID: 30845334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination against typhoid fever in travellers: a cost-effectiveness approach.
    Papadimitropoulos V; Vergidis PI; Bliziotis I; Falagas ME
    Clin Microbiol Infect; 2004 Aug; 10(8):681-3. PubMed ID: 15301670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the overall understanding of typhoid fever: implications for vaccine development.
    O'Reilly PJ; Pant D; Shakya M; Basnyat B; Pollard AJ
    Expert Rev Vaccines; 2020 Apr; 19(4):367-382. PubMed ID: 32238006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Building the case for wider use of typhoid vaccines.
    Crump JA
    Vaccine; 2015 Jun; 33 Suppl 3(Suppl 3):C1-2. PubMed ID: 25910921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating investments in typhoid vaccines in two slums in Kolkata, India.
    Cook J; Sur D; Clemens J; Whittington D
    J Health Popul Nutr; 2009 Dec; 27(6):711-24. PubMed ID: 20099754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study.
    Phillips MT; Antillon M; Bilcke J; Bar-Zeev N; Limani F; Debellut F; Pecenka C; Neuzil KM; Gordon MA; Thindwa D; Paltiel AD; Yaesoubi R; Pitzer VE
    BMC Infect Dis; 2023 Mar; 23(1):143. PubMed ID: 36890448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The new problem of typhoid fever in Papua New Guinea: how do we deal with it?
    Passey M
    P N G Med J; 1995 Dec; 38(4):300-4. PubMed ID: 9522872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.